

CLAIMS:

1. A method for detecting a target oligonucleotide in a sample, comprising:
 - (a) providing a sensor device having a sensing interface carrying capturing oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a first portion of the target oligonucleotides wherein said sensor device comprises an electrochemical probe carrying the sensing interface;
 - (b) providing verification oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a second portion of the target oligonucleotide, other than said first portion;
 - (c) contacting the sample with the sensing interface under conditions such as to allow the target oligonucleotides, if present in the sample, to hybridize to the capturing oligonucleotides;
 - (d) prior to (c) or thereafter, allowing the verification oligonucleotides to hybridize to the target oligonucleotides if present in the sample; and
 - (e) detecting the presence of said verification oligonucleotides on the sensing interface.
2. The method of Claim 1, wherein said detection is based on Faradaic impedance spectroscopy or amperometric measurements.
3. The method of either of Claims 1 or 2, wherein the sequence complementary to at least a stably hybridizing portion of the target oligonucleotide is of about 12 nucleotides.
4. The method according of any one of Claims 1-3, wherein the verification oligonucleotide is conjugated to a recognition agent which can specifically bind to a signal-amplifying agent, and step (e) of the method comprises:
 - (e1) contacting the sensing interface with said signal-amplifying agent;
 - (e2) detecting the presence of said signal-amplifying agent on the sensing interface.
5. The method of Claim 4, wherein said recognition agent is biotin and said signal amplifying agent comprises avidin.
6. The method of any one of Claims 1-3, wherein said verification oligonucleotide is bound to or complexed with a signal-amplifying agent, and step

(e) comprises detecting of presence of the signal-amplifying agent on the sensing interface.

7. The method of any one of Claims 1-3, wherein the verification oligonucleotide comprises a first recognition agent which specifically binds to a recognition partner to form a recognition couple, step (e) of the method comprises the following steps:

- (e1) contacting said sensing interface with said recognition partner;
- (e2) contacting said sensing interface with a signal-amplifying agent comprising a second recognition agent, which may be the same or different as the first recognition agent, which can also bind to said recognition partner; and
- (e3) detecting presence of said signal-amplifying agent on said sensing interface.

8. The method of Claim 7, comprising the following step between steps (e2) and (e3):

- (e2.1) repeating steps (e1) and (e2) one or more times.

9. The method of any one of Claims 4-8, wherein said signal-amplifying agent comprises an enzyme which catalyzes a reaction yielding an insoluble reaction product, and step (e) comprises:

- (ea) providing conditions permitting catalytic activity of said enzyme to yield formation of said insoluble reaction product; and
- (eb) detecting the presence of said insoluble reaction product on said sensing interface.

10. The method of any one of Claims 4-8, wherein said signal-amplifying agent comprises a moiety or a particle which directly increases the mass immobilized on the sensing surface, the method comprises in step (e):

- (ea) detecting the presence of said moiety or particle on said sensing interface.

11. The method of Claim 10, wherein said moiety is a molecule or a super molecular structure.

12. A system for detecting a target oligonucleotide in a sample, comprising:

(i) a sensor device having a sensing interface carrying capturing oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a first portion of the target oligonucleotides wherein said sensor device is an electrochemical electrode carrying said sensing interface;

(ii) verification oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a second portion of the target oligonucleotide, other than said first portion; and

(iii) a detecting means comprising one or both of apparatus and reagents for detecting a verification oligonucleotide bound to the sensing interface.

13. The system of Claim 12, wherein when the system comprises an apparatus, said apparatus is adapted for the performance of an electrochemical measurement.

14. The system of either of Claims 12 or 13, wherein said capturing oligonucleotide has a nucleotide sequence complementary to said first portion which has a length of about 12 nucleotides.

15. The system of any one of Claims 12-14, wherein the verification oligonucleotide is conjugated to a recognition agent which specifically binds to a signal-amplifying agent.

16. The system of Claim 15, wherein said recognition agent is biotin and said signal-amplifying agent comprises avidin.

17. The system of any one of Claims 12-14, wherein the verification oligonucleotide is conjugated or complexed with a signal-amplifying agent.

18. A system of any one of Claims 12-14, wherein the verification oligonucleotide is conjugated to a first recognition agent, which specifically binds to a recognition partner, the recognition partner being capable of binding also to a second recognition agent, being the same or different from said first recognition agent; the system further comprises a signal amplifying agent comprising a second recognition agent.

19. A system of Claim 18, when said first and said second recognition agents are biotin and where said recognition partner is avidin or streptavidin.

20. A system of any one of Claims 12-19, wherein said signal-amplifying agent comprises an enzyme which catalyzes a reaction yielding an insoluble reaction product.

21. A system of any one of Claims 12-19, wherein said signal-amplifying agent comprises a particle or moiety which directly increases the mass immobilized on the sensing interface.
22. For use in the method of any one of Claims 1-11 or the system of any one of Claims 12-21, a reagent being at least one member of the group consisting of:
- (i) said verification oligonucleotide;
 - (ii) an amplifying agent for amplifying the signal resulting from binding of said verification oligonucleotide to said sensing interface.
23. A method for detecting a target oligonucleotide in a sample, comprising:
- (a) providing a sensor device having a sensing interface carrying capturing oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a first portion of the target oligonucleotides;
 - (b) providing verification oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a second portion of the target oligonucleotide, other than said first portion, wherein the verification oligonucleotide is capable of binding to a signal-amplifying agent comprising a liposome,
 - (c) contacting the sample with the sensing interface under conditions so as to allow the target oligonucleotides, if present in the sample, to hybridize to the capturing oligonucleotides;
 - (d) prior to (c) or thereafter, allowing the verification oligonucleotides to hybridize to the target oligonucleotides if present in the sample;
 - (e) contacting the sensing interface with said signal-amplifying agent; and
 - (f) detecting the presence of said signal-amplifying agent on the sensing interface.
24. The method of Claim 23, wherein said sensor device comprises an electrochemical probe carrying the sensing interface.
25. The method of Claim 24, wherein said detection is based on Faradaic impedance spectroscopy or amperometric measurements.
26. The method of Claim 23, wherein said sensor device comprises a microbalance quartz-crystal probe carrying the sensing interface.

27. The method of Claim 26, wherein said detection is based on a microgravimetric quartz-crystal microbalance (QCM) analysis.
28. The method of any one of Claims 23-27, wherein the sequence complementary to at least a stably hybridizing portion of the target oligonucleotide is of about 12 nucleotides.
29. The method according of any one of Claims 23-28, wherein the verification oligonucleotide is conjugated to a recognition agent which can specifically bind to said signal-amplifying agent.
30. The method of Claim 29, wherein said recognition agent is biotin and said signal amplifying agent comprises avidin.
31. The method of any one of Claims 23-28, wherein said verification oligonucleotide is bound to or complexed with said signal-amplifying agent.
32. The method of any one of Claims 23-28, wherein the verification oligonucleotide comprises a first recognition agent which specifically binds to a recognition partner to form a recognition couple, step (e) of the method comprising the following steps:
- (e1) contacting said sensing interface with said recognition partner;
 - (e2) contacting said sensing interface with said signal-amplifying agent comprising a second recognition agent, which may be the same or different as the first recognition agent, which can also bind to said recognition partner.
33. The method of Claim 32, comprising the following step after step (e2):
- (e2.1) repeating steps (e1) and (e2) one or more times.
34. A system for detecting a target oligonucleotide in a sample, comprising:
- (i) a sensor device having a sensing interface carrying capturing oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a first portion of the target oligonucleotides;
 - (ii) verification oligonucleotides having each a nucleotide sequence complementary in at least a stably hybridizing portion thereof to a second portion of the target oligonucleotide, other than said first portion, wherein the verification oligonucleotide is capable of binding to a signal-amplifying agent comprising a liposome; and

(iii) a detecting means comprising one or both of apparatus and reagents for detecting a verification oligonucleotide bound to the sensing interface, wherein said detecting means comprises said signal-amplifying agent comprising a liposome.

35. The system of Claim 34, wherein said sensor device is an electrochemical electrode carrying said sensing surface.

36. The system of Claim 34 or 35, wherein said apparatus is adapted for the performance of an electrochemical measurement.

37. The system of Claim 34, wherein said sensor device comprises a microbalance quartz-crystal probe carrying the sensing interface.

38. The system according to Claim 37, wherein said detection is based on a microgravimetric quartz-crystal microbalance (QCM) analysis.

39. The system of Claims 34-38, wherein said capturing oligonucleotide has a nucleotide sequence complementary to said first portion which has a length of about 12 nucleotides.

40. The system of any one of Claims 34-39, wherein the verification oligonucleotide is conjugated to a recognition agent which specifically binds to the signal-amplifying agent.

41. The system of Claim 40, wherein said recognition agent is biotin and said signal-amplifying agent comprises avidin.

42. The system of any one of Claims 34-39, wherein the verification oligonucleotide is conjugated or complexed with the signal-amplifying agent.

43. A system of any one of Claims 34-39, wherein the verification oligonucleotide is conjugated to a first recognition agent, which specifically binds to a recognition partner, the recognition partner being capable of binding also to a second recognition agent, being the same or different from said first recognition agent; the system further comprises the signal amplifying agent comprising a second recognition agent.

44. A system of Claim 43, when said first and said second recognition agents are biotin and where said recognition partner is avidin or streptavidin.

45. For use in the method of any one of Claims 23-33 or the system of any one of Claims 34-44, a reagent being at least one member of the group consisting of:

- (i) said verification oligonucleotide;

Figure 1 consists of 12 sub-graphs labeled (a) through (l), each showing the growth of *E. coli* O157:H7 in ground beef under different treatment conditions. The y-axis for all graphs is \log_{10} CFU/g, ranging from 0 to 10. The x-axis is time in hours, ranging from 0 to 120. The graphs show various growth curves, with some treatments showing significant inhibition of growth compared to the control.

- (a) Control: Shows a steady increase in bacterial count from approximately 10^1 to 10^8 CFU/g over 120 hours.
- (b) Salt: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (c) Acetic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (d) Lactic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (e) Citric acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (f) Malic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (g) Succinic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (h) Tartaric acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (i) Fumaric acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (j) Gluconic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (k) Mannic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.
- (l) Oxalic acid: Shows a slight increase in bacterial count from approximately 10^1 to 10^2 CFU/g over 120 hours.